Lundbeck Q3 2019 Financial Results

Two large pivotal studies including -2,000 patients demonstrated sustained efficacy and good tolerability PROMISE 1 in Episodic Migraine Patients (N=888; baseline -9 migraine days/month) PROMISE 2 in Chronic Migraine Patients (N=1,072; baseline - 16 migraine days/month) Met primary and all key secondary endpoints Good tolerability profile at both dosage levels POWERFUL ≥50%, ≥75% and 100% reductions in migraine days FAST Onset of prevention Day One post-infusion * Met primary and key * secondary endpoints * Good tolerability profile at all dosage levels * 16 + SUSTAINED for 3 months following a single administration and sustained or further increased with subsequent infusions Lundbeck

View entire presentation